Results 91 to 100 of about 70,073 (274)

Identification of genetically predicted protein biomarkers and drug targets for prostate cancer via Mendelian randomization

VIEW, EarlyView.
Prostate cancer, a leading cause of cancer in men globally, urgently requires improved diagnostic and treatment strategies. This study analyzed large genetic datasets and identified five key proteins (THBD, DST, IFI27L2, OSBPL10, PPP1R14A) that either increase or decrease cancer risk, while also exploring their roles in immune response and potential ...
Maoping Cai, Tianming Peng, Zhiyue Xie, Chuqian Zhen, Chen Yao, Nan Peng, Qianyi Li, Yuzhong Yu, Jiming Bao, Xian‐Lu Song, Mingkun Chen, Shan‐Chao Zhao   +11 more
wiley   +1 more source

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer

Nature Communications, 2020
MUC1-C is overexpressed in castration-resistant prostate cancer and neuroendocrine prostate cancer. Here, the authors show that MUC1-C drives lineage plasticity through MYC and BRN2, inducing neuroendocrine features and stemness in prostate cancer.
Yota Yasumizu, Hasan Rajabi, Caining Jin, Tsuyoshi Hata, Sean Pitroda, Mark D. Long, Masayuki Hagiwara, Wei Li, Qiang Hu, Song Liu, Nami Yamashita, Atsushi Fushimi, Ling Kui, Mehmet Samur, Masaaki Yamamoto, Yan Zhang, Ning Zhang, Deli Hong, Takahiro Maeda, Takeo Kosaka, Kwok K. Wong, Mototsugu Oya, Donald Kufe   +22 more
doaj   +1 more source

About sorafenib in castration-resistant prostate cancer

Annals of Oncology, 2008
n ...
Colloca, G., Checcaglini, F., Venturino, A.   +2 more
openaire   +3 more sources

Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer

Frontiers in Oncology, 2019
Prostate cancer is the most commonly diagnosed cancer affecting men in the United States. The prostate is a hormone-dependent gland in which androgen hormones testosterone and dihydrotestosterone bind to and activate the androgen receptor, initiating ...
Meghan A. Rice, S. Malhotra, Tanya Stoyanova   +2 more
semanticscholar   +1 more source

Utility of SUVmax on Primary Staging 68Ga‐PSMA PET in Determining Metastatic Status of Prostate Cancer

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Introduction 68Ga prostate‐specific membrane antigen (PSMA) has been shown to have prognostic value in detecting PSMA expressing metastasis from prostate cancer, but inevitably, there are cases in which suspected metastases demonstrate equivocal uptake.
Geoffrey Liu, Shane Lee, Kabir Ahmad
wiley   +1 more source

Post‐Therapeutic Dosimetry of Metastatic Castration‐Resistant Prostate Cancer With 177Lu‐PSMA: Experiences From Two University‐Based Hospitals in Thailand

Asia-Pacific Journal of Clinical Oncology, EarlyView.
ABSTRACT Objective 177Lu‐PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration‐resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing 177Lu‐PSMA‐RLT from two university ...
Onnicha Pattanawong, Putthiporn Charoenphun, Wichana Chamroonrat, Thonnapong Thongpraparn, Nucharee Poon‐iad, Benjapa Khiewvan, Krisanat Chuamsaamarkkee   +6 more
wiley   +1 more source

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses

Nature Communications, 2018
The functional significance of the observed heterogeneity of androgen receptor (AR) expression in prostate cancer is unknown. Here the authors show AR expression heterogeneity is associated with distinct castration/enzalutamide responses and identify BCL-
Qiuhui Li, Qu Deng, Hsueh-Ping Chao, Xin Liu, Yue Lu, Kevin Lin, Bigang Liu, Gregory W. Tang, Dingxiao Zhang, Amanda Tracz, Collene Jeter, Kiera Rycaj, Tammy Calhoun-Davis, Jiaoti Huang, Mark A. Rubin, Himisha Beltran, Jianjun Shen, Gurkamal Chatta, Igor Puzanov, James L. Mohler, Jianmin Wang, Ruizhe Zhao, Jason Kirk, Xin Chen, Dean G. Tang   +24 more
doaj   +1 more source

Chemotherapy options in castration-resistant prostate cancer

Indian Journal of Urology, 2016
The treatment landscape for patients with metastatic castration-resistant prostate cancer (CRPC) is evolving, with recent approvals of immune therapy, novel hormonal therapy, and bone-targeted therapy. Chemotherapy remains an essential component of the armamentarium.
Benjamin A Teply, Ralph J Hauke
openaire   +3 more sources

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.

The Lancet Oncology, 2019
BACKGROUND Abiraterone acetate plus prednisone and enzalutamide are both used for the treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best sequence in which to use both drugs, as well as their second-line efficacy.
D. Khalaf, Matti Annala, S. Taavitsainen, D. Finch, C. Oja, J. Vergidis, M. Zulfiqar, K. Sunderland, A. Azad, C. Kollmannsberger, B. Eigl, K. Noonan, D. Wadhwa, A. Attwell, B. Keith, S. Ellard, L. Lê, M. Gleave, A. Wyatt, K. Chi   +19 more
semanticscholar   +1 more source

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae‐Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallick, Chi Fai Ng, Pei Ing Ngam, Teng Aik Ong, Jacob Pang, Darren M. C. Poon, Natasha Roberts, Marniza Saad, Shinichi Sakamoto, Jeremy Tey, Sue Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Alvin Wong, Yao Zhu, ANZUP Cancer Trials Group, Ian D. Davis   +28 more
wiley   +1 more source